12/23
04:06 am
alvo
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 [Yahoo! Finance]
Low
Report
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 [Yahoo! Finance]
12/23
04:00 am
alvo
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
Low
Report
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
12/16
11:20 am
alvo
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade [Yahoo! Finance]
12/16
09:38 am
alvo
Exploring Three High Growth Tech Stocks in the United States [Yahoo! Finance]
Low
Report
Exploring Three High Growth Tech Stocks in the United States [Yahoo! Finance]
11/21
02:04 am
alvo
Alvotech's Position In The Coming Biosimilar Gold Rush [Seeking Alpha]
Low
Report
Alvotech's Position In The Coming Biosimilar Gold Rush [Seeking Alpha]
11/15
02:22 am
alvo
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements [Yahoo! Finance]
Low
Report
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements [Yahoo! Finance]
11/13
09:26 pm
alvo
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates [Yahoo! Finance]
Medium
Report
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates [Yahoo! Finance]
11/13
04:22 pm
alvo
Alvotech Reports Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
Medium
Report
Alvotech Reports Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
11/13
04:05 pm
alvo
Alvotech Reports Financial Results for the First Nine Months of 2024
Medium
Report
Alvotech Reports Financial Results for the First Nine Months of 2024
11/7
08:00 am
alvo
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
Low
Report
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
11/4
07:00 am
alvo
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
Low
Report
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
10/30
08:30 am
alvo
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
Low
Report
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
10/25
08:00 am
alvo
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
Low
Report
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
10/23
07:33 am
alvo
FDA approves Alvotech and Teva's SELARSDI for new indications [Yahoo! Finance]
Medium
Report
FDA approves Alvotech and Teva's SELARSDI for new indications [Yahoo! Finance]
10/22
07:09 am
alvo
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) [Financial Post (Toronto, Ontario, Canada)]
10/22
07:00 am
alvo
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Low
Report
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
10/10
05:05 am
alvo
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® [Yahoo! Finance]
Low
Report
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® [Yahoo! Finance]
10/10
05:00 am
alvo
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Low
Report
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®